Overview
Rev Panam Salud Publica 40(6), 2016
Washington, D.C., USA, 23-27 September 2018
Provisional Agenda Item 4.6
CD56/10, Rev. 1 31 August 2018
Original: Spanish
Washington, D.C., ÉUA, du 26 au 30 septembre 2016
Point 4.10 de l’ordre du jour provisoire
CD55/14 8 juillet 2016
Original : anglais
Washington, D.C., EUA, 26 a 30 de setembro de 2016
Tema 4.10 da agenda provisória
CD55/14 8 de julho de 2016
Original: inglês
Washington, D.C., EUA, del 26 al 30 de septiembre del 2016
Punto 4.10 del orden del día provisional
CD55/14 8 de julio del 2016
Original: inglés
Technical Report
AIDS Medicines and diagnostics service
September 2016
A resource for improving menstraul hygiene around the world.
Comprehensive guidance with examples of good practice, information for colleagues and pupils in class and tips on how to break the taboo
World Health Organization Department of Reproductive Health and Research
Brocher Foundation, Hermance, Geneva, Switzerland, 27–29 April 2016
Clinical Guidance across the continuum of care
Chapter 8_ARV Guidelines
Accelerating HIV prevention to reduce new infections by 75%
Октябрь 2017
Русский
Рекомендации EACS 9.0
Médecins sans Frontières access campaign
Issue Brief
Accessed: 28.11.2019
Of the 50 antibiotics in the pipeline, 32 target WHO priority pathogens but the majority have only limited benefits when compared to existing antibiotics. Two of these are active against the multi-drug resistant Gram-negative bacteria, which are spreading rapidly and require urgent solutions.
Gr...am-negative bacteria, such as Klebsiella pneumoniae and Escherichia coli, can cause severe and often deadly infections that pose a particular threat for people with weak or not yet fully developed immune systems, including newborns, ageing populations, people undergoing surgery and cancer treatment.
The report highlights a worrying gap in activity against the highly resistant NDM-1 (New Delhi metallo-beta-lactamase 1), with only three antibiotics in the pipeline. NDM-1 makes bacteria resistant to a broad range of antibiotics, including those from the carbapenem family, which today are the last line of defence against antibiotic-resistant bacterial infections.
more
Evaluating the Return on Investment of Scaling Up Treatment for Depression, Anxiety, and Psychosis